MONALEESA-3: Quality of Life Analysis
Ribociclib plus fulvestrant for advanced breast cancer
Key Finding: Ribociclib plus fulvestrant demonstrated a trend toward delaying deterioration in Global Health Status and Pain scores compared to placebo, while maintaining overall Quality of Life.
Study Design & Arms
Randomized comparison of Ribociclib vs Placebo in combination with Fulvestrant.
Baseline Global Health Status (QOL)
Mean scores at baseline were well balanced between the two arms.
Time to Deterioration: Global Health Status
Median months to ≥10% deterioration. Higher is better.
Time to Deterioration: Functioning
Comparison of Mean TTD for Physical and Emotional Functioning.
Time to Deterioration: Pain Severity (BPI-SF)
Median months to ≥10% deterioration in Pain Severity Index.
Benefit Summary: Months Gained
Difference in Time to Deterioration (Ribociclib - Placebo) across metrics.
Appendix: Raw Data & Provenance
| Metric | Group | Value | Source |
|---|